Atomo Diagnostics Ltd Market Cap ($8.30 Million)
Market Cap & Net Worth: Atomo Diagnostics Ltd (AT1)
Atomo Diagnostics Ltd market cap. Atomo Diagnostics Ltd (AU:AT1) has a market capitalization of $8.30 Million (AU$11.73 Million) as of November 12, 2026. Listed on the AU stock exchange, this Australia-based company holds position #27368 globally and #1317 in its home market, demonstrating a -7.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Atomo Diagnostics Ltd's stock price AU$0.01 by its total outstanding shares 902432853 (902.43 Million). Also see cash flow conversion of Atomo Diagnostics Ltd for how efficiently the company converts equity into cash flow.
Atomo Diagnostics Ltd Market Cap History (2020–2026)
Atomo Diagnostics Ltd market cap history from 2020 to 2026. Data shows change from $194.75 Million to $8.30 Million (-40.39% CAGR). Check today's stock price for Atomo Diagnostics Ltd for real-time trading data and today's change.
Atomo Diagnostics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Atomo Diagnostics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Atomo Diagnostics Ltd net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
6.06x
Atomo Diagnostics Ltd's market cap is 6.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $194.75 Million | $5.37 Million | -$9.22 Million | 36.28x | N/A |
| 2021 | $191.56 Million | $6.72 Million | -$6.02 Million | 28.52x | N/A |
| 2022 | $34.48 Million | $12.34 Million | -$5.71 Million | 2.80x | N/A |
| 2023 | $14.05 Million | $2.54 Million | -$9.96 Million | 5.52x | N/A |
| 2024 | $12.13 Million | $4.09 Million | -$6.85 Million | 2.97x | N/A |
| 2025 | $22.99 Million | $3.79 Million | -$4.97 Million | 6.06x | N/A |
Competitor Companies of AT1 by Market Capitalization
Companies near Atomo Diagnostics Ltd in the global market cap rankings as of November 12, 2026. Also see Atomo Diagnostics Ltd asset portfolio for a full breakdown of the balance sheet.
Key companies related to Atomo Diagnostics Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #114 globally with a market cap of $190.04 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #201 globally with a market cap of $122.28 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #225 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #114 | Abbott Laboratories | NYSE:ABT | $190.04 Billion | $109.29 |
| #201 | Stryker Corporation | NYSE:SYK | $122.28 Billion | $318.79 |
| #225 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $101.61 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Atomo Diagnostics Ltd (2020–2026)
Market capitalization of Atomo Diagnostics Ltd from 2020 to today. Between 2020 and today, Atomo Diagnostics Ltd's market cap moved from $194.75 Million to $ 8.30 Million, with a yearly change of -40.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$8.30 Million | -63.89% |
| 2025 | AU$22.99 Million | +89.47% |
| 2024 | AU$12.13 Million | -13.64% |
| 2023 | AU$14.05 Million | -59.26% |
| 2022 | AU$34.48 Million | -82.00% |
| 2021 | AU$191.56 Million | -1.64% |
| 2020 | AU$194.75 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 12th, 2026 the market cap of Atomo Diagnostics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.30 Million USD |
| MoneyControl | $8.30 Million USD |
| MarketWatch | $8.30 Million USD |
| marketcap.company | $8.30 Million USD |
| Reuters | $8.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Atomo Diagnostics Ltd
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-Test device; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.